Skip to main content

Articles

Original Research, Practice Management
Budget Impact of Adding Vedolizumab to a Health Plan Formulary as Another First-Line Biologic Option for Ulcerative Colitis and Crohn’s Disease
Michele Wilson, MSPH; Aaron Lucas, PhD, MPH; Ann Cameron, MA, PhD; Michelle Luo, PhD
Read More
Perspectives
Namaste
David B. Nash, MD, MBA
Read More
Original Research
Assessing the Level of Patient-Specific Treatment Recommendations in Clinical Practice Guidelines for Hemodialysis Vascular Access in the United States
Gilbert L. Queeley, PhD; Ellen S. Campbell, PhD; Askal A. Ali, PhD
Stakeholder Perspective
The Challenge of Maintaining Vascular Access in Patients with End-Stage Renal Disease
Raymond L. Singer, MD, MMM, CPE
Read More
Perspectives
Can We Make Medicines Affordable?
David B. Nash, MD, MBA
Read More
Original Research, Practice Management
Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy
Machaon M. K. Bonafede, PhD, MPH; Donna McMorrow, BS; Clare Proudfoot, PhD; Shraddha Shinde, MS, MBA; Andreas Kuznik, PhD; Chieh-I Chen, MPH
Read More
Original Research
Prior Authorization for Elective Diagnostic Catheterization: The Value of Reviewers in Cases with Clinical Ambiguity
Adam C. Powell, PhD; Stephen E. Price, DPT, MBA; Khoa Nguyen, MS; Gary L. Smith, MS; James W. Long, BSBA; Uday U. Deshmukh, MD, MPH
Stakeholder Perspective
Standardized Documentation Can Improve Diagnostic Testing Decisions for Patients with Cardiovascular Disease
Raymond L. Singer, MD, MMM, CPE, FACS
Read More
Conference Highlights AMCP
Can Technologic Innovations and Formulary Considerations Improve Healthcare Outcomes?
Charles Bankhead
Read More
Original Research
Long-Term Outcomes of a Cardiovascular and Diabetes Risk-Reduction Program Initiated by a Self-Insured Employer
Nicole D. White, PharmD, CDE; Thomas L. Lenz, PharmD, FACLM; Maryann Z. Skrabal, PharmD, CDE; Jessica J. Skradski, PharmD; Louis Lipari, PharmD candidate
Stakeholder Perspective
Influencing Patient Outcomes Through Enhanced Multidisease-Focused Interventions
Jack E. Fincham, PhD, RPh
Read More
FDA Approvals
Oncology Drugs Approved by the FDA in Early 2018
Read More
FDA Approvals
A “Gold Standard” for Population Health? Revisiting the FDA’s Relationship with the Hippocratic Oath
Read More
Page 70 of 244
Results 691 - 700 of 2434